Neuropathy Screening and Diagnosis Market - 2024-2031

February 2026 | 60 pages | ID: NAB7B3B34731EN
DataM Intelligence

Abstracts

Neuropathy Screening and Diagnosis Marketis is growing with a CAGR of 6.70% during the forecast period 2026-2035.

The Neuropathy Screening and Diagnosis Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Neuropathy Screening and Diagnosis Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Disease Type

• Autonomic *
• Diabetic Neuropathy
• Peripheral Neuropathy
• Focal Neuropathy
• Poly Neuropathy

By Diagnosis Test

• Sensory Testing*
• Nerve Conduction Testing
• Electromyography
• Autonomic Testing
• Skin Biopsy
• MRI Scanning
• Others

By End-User

• Hospitals*
• Neurology Clinics
• Academic and Research Institutes
• Others

Regional Analysis for Neuropathy Screening and Diagnosis Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Neuropathy Screening and Diagnosis Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Disease Type
3.2. Snippet by Diagnosis Test
3.3. Snippet by End-User
3.4. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Increasing Prevalence of Neuropathy
    4.1.1.2. Advancements In Research and Diagnostics
  4.1.2. Restraints
    4.1.2.1. High cost associated with diagnostic techniques
    4.1.2.2. Stringent Regulatory Compliance
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis

6. BY DISEASE TYPE

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  6.1.2. Market Attractiveness Index, By Disease Type
6.2. Autonomic *
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Diabetic Neuropathy
6.4. Peripheral Neuropathy
6.5. Focal Neuropathy
6.6. Poly Neuropathy

7. BY DIAGNOSIS TEST

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
  7.1.2. Market Attractiveness Index, By Diagnosis Test
7.2. Sensory Testing*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Nerve Conduction Testing
7.4. Electromyography
7.5. Autonomic Testing
7.6. Skin Biopsy
7.7. MRI Scanning
7.8. Others

8. BY END-USER

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  8.1.2. Market Attractiveness Index, By End-User
8.2. Hospitals*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Neurology Clinics
8.4. Academic and Research Institutes
8.5. Others

9. BY REGION

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  9.1.2. Market Attractiveness Index, By Region
9.2. North America
  9.2.1. Introduction
  9.2.2. Key Region-Specific Dynamics
  9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
  9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.2.6.1. The U.S.
    9.2.6.2. Canada
    9.2.6.3. Mexico
9.3. Europe
  9.3.1. Introduction
  9.3.2. Key Region-Specific Dynamics
  9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
  9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.3.6.1. Germany
    9.3.6.2. UK
    9.3.6.3. France
    9.3.6.4. Italy
    9.3.6.5. Spain
    9.3.6.6. Rest of Europe
9.4. South America
  9.4.1. Introduction
  9.4.2. Key Region-Specific Dynamics
  9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
  9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.4.6.1. Brazil
    9.4.6.2. Argentina
    9.4.6.3. Rest of South America
9.5. Asia-Pacific
  9.5.1. Introduction
  9.5.2. Key Region-Specific Dynamics
  9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
  9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.5.6.1. China
    9.5.6.2. India
    9.5.6.3. Japan
    9.5.6.4. South Korea
    9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
  9.6.1. Introduction
  9.6.2. Key Region-Specific Dynamics
  9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
  9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. COMPETITIVE LANDSCAPE

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. COMPANY PROFILES

11.1. Eli Lilly And Company *
  11.1.1. Company Overview
  11.1.2. Product Portfolio and Description
  11.1.3. Financial Overview
  11.1.4. Key Developments
11.2. Reddy’s Laboratories
11.3. Pfizer Inc.
11.4. Cipla
11.5. Abbott Laboratories
11.6. Lupin Ltd.
11.7. NeuroBo Pharmaceuticals Inc.
11.8. NeuroMetrix Inc.
11.9. Glenmark Pharmaceuticals
11.10. Teva Pharmaceuticals (*LIST NOT EXHAUSTIVE)

12. APPENDIX

12.1. About Us and Services
12.2. Contact Us